Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALDH1 siRNA
- Development stage
- Preclinical
- Lead developer
- Santa Cruz Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
ALDH1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Aldehyde Dehydrogenase 1 (ALDH1), a cytosolic enzyme that serves as a functional marker for cancer stem cells (CSCs) and plays a critical role in cellular detoxification and retinoic acid biosynthesis. In various malignancies, high ALDH1 activity is associated with increased tumorigenicity, chemoresistance, and poor clinical outcomes. ALDH1 siRNA acts through the RNA interference (RNAi) pathway, where it facilitates the sequence-specific degradation of ALDH1 mRNA (most commonly the ALDH1A1 or ALDH1A3 isoforms). This reduction in ALDH1 protein levels sensitizes cancer cells to chemotherapeutic agents, impairs the self-renewal and maintenance of CSC populations, and inhibits tumor growth and metastasis. While primarily utilized as a research tool in preclinical studies, ALDH1 siRNA is also being investigated in translational oncology using advanced delivery systems such as lipid nanoparticles to overcome the challenges of systemic RNA delivery.
- Other names
- ALDH1A1 siRNAALDH-1A1 siRNAALDH 1A1 siRNAALDH1A3 siRNAALDH-1A3 siRNAALDH 1A3 siRNAsiALDH1siALDH-1siALDH 1
02
Targets
ALDH1A3 (Aldehyde dehydrogenase 1 family member A3)ALDH1A2 (Aldehyde dehydrogenase 1 family member A2)Aldehyde dehydrogenase 1 family member A1 mRNA
Beyond the preview
Go deeper on ALDH1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALDH1 siRNA.